Revolution Medicines reinforced momentum behind its KRAS program at the American Association for Cancer Research meeting with updated clinical results for daraxonrasib in advanced pancreatic cancer. Company updates highlighted continued first-line and combination-oriented activity, adding to the dataset that has positioned daraxonrasib as a potential option in a high-unmet-need setting. Separately, the company outlined preclinical work on RM-055, which RevMed described as a “novel class” of catalytic inhibitors aimed at turning off RAS-driven signaling at the molecular level. The meeting coverage reflects intensified effort across KRAS variants and downstream biology after the field’s long search for durable, clinically meaningful responses.